BR112012005140A2 - inibidores de hsl úteis no tratamento de diabetes - Google Patents

inibidores de hsl úteis no tratamento de diabetes

Info

Publication number
BR112012005140A2
BR112012005140A2 BR112012005140A BR112012005140A BR112012005140A2 BR 112012005140 A2 BR112012005140 A2 BR 112012005140A2 BR 112012005140 A BR112012005140 A BR 112012005140A BR 112012005140 A BR112012005140 A BR 112012005140A BR 112012005140 A2 BR112012005140 A2 BR 112012005140A2
Authority
BR
Brazil
Prior art keywords
treating diabetes
inhibitors useful
hsl inhibitors
hsl
useful
Prior art date
Application number
BR112012005140A
Other languages
English (en)
Inventor
Aurelia Conte
Jean Ackermann
Matthias Nettekoven
Stanley Wertheimer
Werner Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012005140A2 publication Critical patent/BR112012005140A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112012005140A 2009-09-11 2010-09-07 inibidores de hsl úteis no tratamento de diabetes BR112012005140A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170071 2009-09-11
PCT/EP2010/063078 WO2011029808A1 (en) 2009-09-11 2010-09-07 Hsl inhibitors useful in the treatment of diabetes

Publications (1)

Publication Number Publication Date
BR112012005140A2 true BR112012005140A2 (pt) 2016-05-03

Family

ID=42983383

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012005140A BR112012005140A2 (pt) 2009-09-11 2010-09-07 inibidores de hsl úteis no tratamento de diabetes

Country Status (17)

Country Link
US (1) US8258158B2 (pt)
EP (1) EP2475644B1 (pt)
JP (1) JP5642793B2 (pt)
KR (1) KR101369551B1 (pt)
CN (1) CN102498099B (pt)
AR (1) AR078351A1 (pt)
AU (1) AU2010294326A1 (pt)
BR (1) BR112012005140A2 (pt)
CA (1) CA2771452A1 (pt)
ES (1) ES2445166T3 (pt)
HK (1) HK1169993A1 (pt)
IL (1) IL217966A0 (pt)
IN (1) IN2012DN01232A (pt)
MX (1) MX2012002597A (pt)
SG (1) SG179031A1 (pt)
TW (1) TW201114744A (pt)
WO (1) WO2011029808A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350121B (es) 2011-03-18 2017-08-28 Bayer Ip Gmbh Derivados de n-(3-carbamoilfenil)-1h-pirazol-5-carboxamida y el uso de los mismos para el control de plagas de animales.
EP2892888B1 (en) * 2012-09-10 2018-04-18 Boehringer Ingelheim International GmbH N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof
EP3551618B1 (en) * 2016-12-09 2020-09-16 Boehringer Ingelheim International GmbH Sulfonamides as inhibitors of the uptake of extracellular citrate
GB2560713A (en) * 2017-03-20 2018-09-26 Eternygen Gmbh Inhibitor of citrate transporter
CN110003177B (zh) * 2019-05-28 2021-11-19 沈阳药科大学 含有脲基的苯并咪唑类化合物及应用
CN110003176B (zh) * 2019-05-28 2021-12-21 沈阳药科大学 含有酰胺的苯并咪唑类化合物及其应用
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
WO2022130352A1 (en) * 2020-12-19 2022-06-23 Cadila Healthcare Limited Novel compounds suitable for the treatment of dyslipidemia
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3779339B2 (ja) 1994-03-04 2006-05-24 三井化学株式会社 含フッ素カルボン酸エステル化合物、液晶材料、液晶組成物および液晶素子
EP1087937A1 (en) * 1998-06-17 2001-04-04 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
HUP0401924A3 (en) 2001-11-14 2009-07-28 Schering Corp Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them
AU2006222372B8 (en) * 2005-03-03 2010-04-08 F. Hoffmann-La Roche Ag 1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type II diabetes mellitus
CN101522687A (zh) * 2006-01-30 2009-09-02 阿雷生物药品公司 用于癌症治疗的杂二环噻吩化合物
US20090306048A1 (en) * 2006-06-16 2009-12-10 John Paul Kilburn Pharmaceutical use of substituted piperidine carboxamides
EP1958631A1 (en) 2007-02-14 2008-08-20 AEterna Zentaris GmbH Novel triazole derivatives as ligands of G-protein coupled receptors
US8324250B2 (en) * 2009-03-19 2012-12-04 Hoffmann-La Roche Inc. Piperidine derivatives as NK3 receptor antagonists
US8329904B2 (en) * 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
US8399676B2 (en) * 2009-07-30 2013-03-19 Hoffman-La Roche Inc. Piperidine derivatives

Also Published As

Publication number Publication date
AU2010294326A1 (en) 2012-03-08
JP2013504533A (ja) 2013-02-07
CN102498099B (zh) 2014-10-29
HK1169993A1 (en) 2013-02-15
WO2011029808A1 (en) 2011-03-17
ES2445166T3 (es) 2014-02-28
CA2771452A1 (en) 2011-03-17
JP5642793B2 (ja) 2014-12-17
KR20120059617A (ko) 2012-06-08
AR078351A1 (es) 2011-11-02
CN102498099A (zh) 2012-06-13
IL217966A0 (en) 2012-03-29
US20110065707A1 (en) 2011-03-17
MX2012002597A (es) 2012-04-02
KR101369551B1 (ko) 2014-03-04
SG179031A1 (en) 2012-04-27
EP2475644B1 (en) 2014-01-08
EP2475644A1 (en) 2012-07-18
US8258158B2 (en) 2012-09-04
IN2012DN01232A (pt) 2015-05-15
TW201114744A (en) 2011-05-01

Similar Documents

Publication Publication Date Title
CY2020024I2 (el) Αναστολεiς βητα-λακταμασων
BRPI0919116A2 (pt) método
BRPI0910854A2 (pt) métodos de tratamento
BRPI0906764A2 (pt) Processos
BR112012004707A2 (pt) método
BR112012000624A2 (pt) método
FI20090389A0 (fi) Menetelmä
BR112012005140A2 (pt) inibidores de hsl úteis no tratamento de diabetes
BRPI0911588A2 (pt) processamento de biomassa
BRPI0913059A2 (pt) processamento de biomassa
BRPI0921036A2 (pt) processamento de biomassa
BRPI0912317A2 (pt) método de autenticação
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BRPI0917575A2 (pt) métodos de tratamento de talassemia
DK2313489T3 (da) Fremstillingsmetode
BRPI0921987A2 (pt) processamento de biomassa
BRPI1012526A2 (pt) método
BRPI0918564A2 (pt) inibidores
BRPI1010705A2 (pt) método
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI0920140A2 (pt) método de floculação
DK2310613T3 (da) Forbedret brudled til stigrør
BRPI0915562A2 (pt) tamis melhorado
FR2942407B1 (fr) Procede de photomaquillage et composition de photomaquillage
BRPI0915442A2 (pt) tamis melhorado

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]